KPV

KPV is a naturally occurring tripeptide derived from the C-terminal sequence of α-melanocyte-stimulating hormone (α-MSH). Unlike other melanocortin peptides, KPV exhibits potent anti-inflammatory effects independent of melanocortin receptors.

Anti-Inflammatory: 35-50% reduction in pro-inflammatory cytokines in human epithelial cells; inhibits NF-κB signaling
Intestinal Health: 50% reduction in myeloperoxidase activity; reduces IBD symptoms; protects against colitis-associated cancer via PepT1 pathway
Wound Healing & Tissue Repair: 2× faster epithelial barrier restoration; improved collagen organization and angiogenesis
Antimicrobial Activity: Effective against S. aureus and C. albicans
Drug Delivery Advantages: 35-fold enhanced transdermal penetration with iontophoresis; orally targeted delivery via functionalized nanoparticles
Safety Profile: Avoids corticosteroid-like immunosuppression; effective in patients with melanocortin receptor variants

Dalmasso, G., et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134(1), 166-178. PubMed
Kannengiesser, K., et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of IBD. Inflammatory Bowel Diseases, 14(3), 324-331. PubMed
Land, S.C., et al. (2012). Inhibition of cellular and systemic inflammation by melanocortin-related peptides. Cellular and Molecular Life Sciences, 69(13), 2261-2277. PubMed
Xiao, B., et al. (2017). Orally targeted delivery of KPV via nanoparticles alleviates ulcerative colitis. Molecular Therapy, 25(7), 1628-1640. PMC
Pawar, A.S., et al. (2017). Transdermal iontophoretic delivery of KPV across microporated human skin. Journal of Pharmaceutical Sciences, 106(7), 1811-1816. PubMed

$98.00

Per Unit

In stock